IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Harding, *et al.* CONFIRMATION NO. : 5566

SERIAL NO.: 10/675,470 ART UNIT: 1642

FILING DATE: 09/30/2003 EXAMINER: Nickol, Gary B.

TITLE: *AT_4 Receptor Ligands as Angiogenic, Anti-Angiogenic, and Anti-tumor Agents*

ATTORNEY: John C. Hughs, Northwest Patent Law

Commissioner of Patents
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Office Action mailed June 17, 2004. Reconsideration of the rejection of the claims is respectfully solicited in light of the following amendments and remarks.

Please amend the Application as follows:

In the Specification:

The title has been amended as follows:

AT_4 Receptor Ligands as ~~Angiogenic,~~ Anti-Angiogenic~~,~~ and Anti-tumor Agents

The first paragraph on page 11, lines 18-25, has been changed to read:

Data from discs containing no drug (control), an AT_4 receptor putative agonist (Cpnd 1), or an AT_4 receptor putative antagonist (Cpnds 2-4~~)~~: NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^-, norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$, or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidine-proline-phenylalanine-COO^-). ~~Cmpd 2 is NORLEUAL~~. Each disc contained 10 micrograms of drug. Data is presented as the percent of the total disc area that is vascularized (Mean ± SEM; n=8). These data demonstrate the ability of three putative antagonists (compounds 2-4) to inhibit angiogenesis while the putative agonist (compound 1) exhibited a trend toward enhancing angiogenesis.

In the Claims:

The claims are amended as follows: